Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + autologous bone marrow mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Yuejin Yang
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Oral, Intracoronary
01
Overview
Atorvastatin + autologous bone marrow mesenchymal stem cells (BMMSCs) is a combination therapy being evaluated in the TEAM-AMI Phase 2 clinical trial for the treatment of acute myocardial infarction (AMI) in patients with impaired left ventricular function. The therapy involves the administration of intensive-dose atorvastatin, a small molecule HMG-CoA reductase inhibitor, alongside the intracoronary transplantation of autologous BMMSCs. Atorvastatin is utilized not only for its lipid-lowering capabilities but also for its pleiotropic effects, which include enhancing angiogenesis, reducing inflammation, and improving the survival and retention of the transplanted stem cells within the post-infarct cardiac microenvironment. This investigative approach is led by Dr. Yuejin Yang at Fuwai Hospital, National Center for Cardiovascular Diseases, in Beijing, China.
- Other names
- intensive atorvastatin and autologous BMMSC transplantationatorvastatin and autologous bone marrow mesenchymal stem cell transplantationBMMSC and Atorvastatin
02
Targets
NOS3 (eNOS)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + autologous bone marrow mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + autologous bone marrow mesenchymal stem cells.